No Data
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Shares Could Be 49% Below Their Intrinsic Value Estimate
Zejing Pharmaceutical Report for the Third Quarter of 2024
Health Check: How Prudently Does Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266) Use Debt?
Zelgen Biopharma Presents Phase 1/2 Data for Antitumor Drug at China Oncology Meet
Zaijing Pharmaceuticals (688266.SH): Preliminary data shows that ZG005 has demonstrated good tolerance, safety, and anti-tumor efficacy in the dose-escalation and expansion studies of Phase I/II.
On September 25th, Geelong announced that several clinical research results of new antibodies of Zejing Pharmaceuticals (688266.SH) were selected for the 27th Chinese Clinical Oncology Conference and 2024 CSCO Academic Annual Meeting for oral or poster presentations. Among them, the preliminary results of the clinical trial of the bispecific antibody ZG005 targeting TIGIT/PD-1 for late-stage solid tumor subjects were selected for the special session on the research and development of new anti-tumor drugs and technologies. Preliminary data showed that ZG005 demonstrated good tolerability, safety, and anti-tumor efficacy in the dose escalation and expansion studies of phase I/II.
Suzhou Zelgen Biopharmaceuticals' ZG006 Drug Demonstrates Efficacy in Treating Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Popularity With Investors Under Threat As Stock Sinks 29%No Data
No Data
